Pollak M - Search Results

1

High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.

Liu Z, Yokoyama NN, Blair CA, Li X, Avizonis D, Wu XR, Uchio E, Youssef R, McClelland M, Pollak M, Zi X. Liu Z, et al. Among authors: pollak m. Mol Cancer Ther. 2016 Mar;15(3):430-8. doi: 10.1158/1535-7163.MCT-15-0714-T. Epub 2016 Feb 26. Mol Cancer Ther. 2016. PMID: 26921394 Free PMC article.

2

Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.

Zi X, Zhang J, Agarwal R, Pollak M. Zi X, et al. Among authors: pollak m. Cancer Res. 2000 Oct 15;60(20):5617-20. Cancer Res. 2000. PMID: 11059749

3

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Lu Y, et al. Among authors: pollak m. J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7. doi: 10.1093/jnci/93.24.1852. J Natl Cancer Inst. 2001. PMID: 11752009

4

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.

Lu Y, Zi X, Pollak M. Lu Y, et al. Among authors: pollak m. Int J Cancer. 2004 Jan 20;108(3):334-41. doi: 10.1002/ijc.11445. Int J Cancer. 2004. PMID: 14648698

5

Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.

Lu Y, Zi X, Zhao Y, Pollak M. Lu Y, et al. Among authors: pollak m. Biochem Biophys Res Commun. 2004 Jan 16;313(3):709-15. doi: 10.1016/j.bbrc.2003.12.007. Biochem Biophys Res Commun. 2004. PMID: 14697248

6

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Zakikhani M, et al. Among authors: pollak m. Cancer Res. 2006 Nov 1;66(21):10269-73. doi: 10.1158/0008-5472.CAN-06-1500. Epub 2006 Oct 23. Cancer Res. 2006. PMID: 17062558

7

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Dowling RJ, et al. Among authors: pollak m. Cancer Res. 2007 Nov 15;67(22):10804-12. doi: 10.1158/0008-5472.CAN-07-2310. Cancer Res. 2007. PMID: 18006825

8

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth.

Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Algire C, et al. Among authors: pollak m. Endocr Relat Cancer. 2008 Sep;15(3):833-9. doi: 10.1677/ERC-08-0038. Epub 2008 May 9. Endocr Relat Cancer. 2008. PMID: 18469156

9

Current status and challenges associated with targeting mTOR for cancer therapy.

Dowling RJ, Pollak M, Sonenberg N. Dowling RJ, et al. Among authors: pollak m. BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. BioDrugs. 2009. PMID: 19489650 Review.

10

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.

Zakikhani M, Blouin MJ, Piura E, Pollak MN. Zakikhani M, et al. Among authors: pollak mn. Breast Cancer Res Treat. 2010 Aug;123(1):271-9. doi: 10.1007/s10549-010-0763-9. Epub 2010 Feb 5. Breast Cancer Res Treat. 2010. PMID: 20135346

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

861 results

Search Page

Filters